Navigation Links
ORTHOCON® Announces U.S. Market Launch of HEMASORB®
Date:2/17/2011

IRVINGTON, N.Y., Feb. 17, 2011 /PRNewswire/ -- ORTHOCON, Inc., a developer of implantable products designed to stop the bleeding from and to deliver drugs to bone, today announced the U.S. launch of its first commercial product, the HEMASORB Absorbable Bone Hemostat Matrix.

The HEMASORB Absorbable Bone Hemostat Matrix is a ready to use, biocompatible, water resistant, and absorbable putty that is designed to rapidly stop bleeding when applied to damaged or cut bone. HEMASORB was cleared for market introduction by the U.S. Food and Drug Administration (FDA) via the 510(k) premarket notification process. In 2010, ORTHOCON conducted a limited market introduction of this product under its development name, ORTHOstat.

"We believe that HEMASORB is an innovative product that addresses a substantial market opportunity and has the potential to become a standard of care," said John J. Pacifico, President and Chief Executive Officer of ORTHOCON. "It is easy to use; it satisfies unmet needs and it is cost-effective."

Bleeding from cut bone is a common occurrence in many operative procedures. Excessive bleeding from bone during surgery may impair the surgeon's view of the operative field, may result in the need for blood transfusions and may be associated with post-operative complications. ORTHOCON estimates that over 3.5 million patients undergoing surgeries in the U.S. and Europe each year could benefit from the intra-operative use of HEMASORB.

"HEMASORB is the first commercial product that employs our proprietary Syntinate Technology Platform," commented Richard L. Kronenthal, Ph.D., ORTHOCON's Scientific Founder. "We are currently developing a pipeline of follow-on products that will complement Syntinate's utility as a bone hemostat by exploiting its unique potential to deliver drugs directly to bone."

The Syntinate Technology Platform incorporates biocompatible and absorbable solids and liquids to create a synthetic matrix that, when applied to bone, mechanically blocks bleeding. In addition, these constituents may act as drug reservoirs allowing for site specific and extended delivery of local anesthetics, anti-infective agents, and other drugs.

"We believe that our pipeline of products, beginning with HEMASORB, is very compelling and has the potential to create significant clinical and commercial value," concluded Mr. Pacifico. "We expect that the successful market launch of our HEMASORB Absorbable Bone Hemostat Matrix will prime the market for the future introduction of an array of innovative products."

About ORTHOCON

Founded in 2005, ORTHOCON develops, manufactures, markets, and sells implantable products designed to stop the bleeding from and to deliver drugs to bone.  

ORTHOCON is funded by leading international venture capital investment firms. The company occupies 8,000 square feet at its new, state-of-the-art facility in Irvington, New York.  For more information, please visit www.orthocon.com.


'/>"/>
SOURCE ORTHOCON, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
2. In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. Alere Inc. Announces Fourth Quarter 2010 Results
5. Kips Bay Medical Announces Closing of its $16.5 Million Initial Public Offering of Common Stock
6. 6th Annual New York Stem Cell Summit Announces Spinal Cord Injury Panel Participants
7. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results Teleconference and Webcast
8. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2010 Financial Results
9. Gen-Probe Announces $150 Million Stock Repurchase Plan
10. Genus Oncology, LLC Announces Initiation of Phase I Trial of GO-203-2c in Patients With Solid Tumors
11. Endologix Announces Presentation of Favorable Initial PEVAR Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- Period October – December 2016 Revenues ... SEK -16.4 (-6.4) million Result after tax amounted to SEK ... dilution Cash flow from operating activities amounted to SEK -8.3 ... Period full year ... Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the Cowen and Company 37 th Annual Health ... Tuesday, March 7, 2017 at 11:20 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/cowen38/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/24/2017)...  In conjunction with DURECT Corporation,s (Nasdaq: ... you are invited to listen to a conference call ... Tuesday, March 14, 2017 at 4:30 pm Eastern Time ... webcast of the presentation will be available by accessing ... Relations."  If you are unable to participate during the ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... 27, 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working ... nun. Now, she writes about God, when she isn’t swimming as a performing mermaid. , ... is BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, ...
(Date:2/27/2017)... ... 26, 2017 , ... Miro is the ultimate smart media center that offers ... movies, TV shows and much more apps for user exploration. Its innovative acoustic design ... of 1280 x 720 provides crisp images with remarkable clarity and color. The WiFi ...
(Date:2/27/2017)... BC (PRWEB) , ... February 27, 2017 , ... ... drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ ... to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to ...
(Date:2/27/2017)... ... ... New Jersey ranks among the top five states in the entire nation ... advanced services is growing. , Project WE vs C is a focused two-year ... non-profit partners in their fight against cancer and in support of their shared mission ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an ... world’s first to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house ... is the globally recognised standard that sets out requirements for the technical competence ...
Breaking Medicine News(10 mins):